Analyst Price Target is $34.75
▲ +394.31% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Reneo Pharmaceuticals in the last 3 months. The average price target is $34.75, with a high forecast of $45.00 and a low forecast of $24.00. The average price target represents a 394.31% upside from the last price of $7.03.
Current Consensus is
The current consensus among 4 polled investment analysts is to buy stock in Reneo Pharmaceuticals.
Reneo Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the development of therapies for patients with rare genetic mitochondrial diseases. It develops REN001, a selective peroxisome proliferator-activated receptor delta agonist, which is in Phase IIb clinical trial in patients with primary mitochondrial myopathies, as well as in Phase 1b clinical trial in patients with long-chain fatty acid oxidation disorders and glycogen storage disease type V. The company was incorporated in 2014 and is headquartered in San Diego, California.